Attached files

file filename
8-K - FORM 8-K - ALBEMARLE CORPd381364d8k.htm

Exhibit 99.1

 

   Contact:   
LOGO    Lorin Crenshaw    225.388.7322

Albemarle Reports Second Quarter 2012 Results

 

 

BATON ROUGE, LA – July 17, 2012 –

Second quarter 2012 highlights:

 

 

Quarterly net income of $111.3 million before special items, or $1.24 per share.

 

 

Eleventh consecutive quarter of year-over-year earnings per share growth, excluding specials.

 

 

EBITDA of $180.9 million and EBITDA margin of 26 percent for the quarter, before special items.

 

 

One-time pre-tax charge of $94.7 million related to exit of phosphorous flame retardants business.

 

     Three Months Ended      Six Months Ended  
     June 30,      June 30,  

In thousands, except per share amounts

   2012      2011      2012      2011  

Net sales

   $ 684,894       $ 742,108       $ 1,396,598       $ 1,438,638   

Segment income

   $ 174,927       $ 180,180       $ 349,190       $ 351,780   

Net income attributable to Albemarle Corporation

   $ 37,732       $ 114,159       $ 145,775       $ 220,739   

Diluted earnings per share

   $ 0.42       $ 1.23       $ 1.62       $ 2.38   

Special items per share

   $ 0.82       $ —         $ 0.82       $ —     
  

 

 

    

 

 

    

 

 

    

 

 

 

Diluted earnings per share excluding special items

   $ 1.24       $ 1.23       $ 2.44       $ 2.38   
  

 

 

    

 

 

    

 

 

    

 

 

 

Albemarle Corporation (NYSE: ALB) reported second quarter 2012 earnings of $37.7 million, or $0.42 per share, compared to second quarter 2011 earnings of $114.2 million, or $1.23 per share. Second quarter 2012 results include after-tax charges amounting to $73.6 million, or $0.82 per share, ($94.7 million before tax) in connection with our previously announced plan to exit the phosphorous flame retardants business. The Company reported net sales of $684.9 million in the second quarter of 2012 compared to net sales of $742.1 million in the second quarter of 2011.

Earnings for the first half of 2012 were $145.8 million, or $1.62 per share, compared to $220.7 million, or $2.38 per share, for the first half of 2011. Excluding after-tax charges amounting to $73.6 million, or $0.82 per share ($94.7 million before tax) for special items in the second quarter of 2012, earnings for the first half of 2012 were $219.4 million, or $2.44 per share. Net sales for the first half of 2012 were $1.40 billion compared to $1.44 billion for the first half of 2011.

“I am pleased to announce our second quarter results, which mark our 11th consecutive quarter of year-over-year earnings per share growth,” said Luke Kissam, CEO. “In spite of a challenging economic environment, each of our businesses delivered solid earnings and margins, and Fine Chemistry recorded its highest quarterly earnings ever. While we

 

1


currently are not seeing the increased market demand that we had expected in the second half of the year, our businesses remain fundamentally healthy and strategically well-positioned. We remain focused on delivering value to our customers and solid financial results through these uncertain times.”

Quarterly Segment Results

Catalysts generated net sales of $229.1 million in the second quarter of 2012, a 14 percent decrease from net sales in the second quarter of 2011, due mainly to a mix shift from HPC to FCC as well as unfavorable foreign currency impacts, partially offset by higher overall volumes. Catalysts segment income was $67.1 million in the second quarter of 2012, up 2 percent over second quarter 2011 results of $65.6 million due primarily to lower input costs, offset mainly by lower equity income versus the second quarter of 2011.

Polymer Solutions delivered net sales of $247.0 million in the second quarter of 2012, a 15 percent decrease over net sales in the second quarter of 2011, due mainly to lower volumes and unfavorable foreign currency impacts, partly offset by favorable pricing. Segment income for Polymer Solutions was $64.1 million in the second quarter of 2012, a 17 percent decline from $77.2 million in the second quarter of 2011, due primarily to lower volumes, partly offset by favorable pricing, lower input costs and lower charges attributable to the noncontrolling interest in our Jordanian joint venture.

Fine Chemistry net sales in the second quarter of 2012 were $208.7 million, a 13 percent increase over net sales in the second quarter of 2011, due mainly to favorable volumes and pricing, partly offset by unfavorable foreign currency impacts. Segment income for Fine Chemistry was $43.8 million for the second quarter of 2012, up 17 percent over second quarter 2011 results of $37.4 million, due primarily to favorable volume and pricing and lower charges attributable to the noncontrolling interest in our Jordanian joint venture, partly offset by higher input costs.

Corporate and Other

Corporate and other expense was $18.6 million for the second quarter of 2012. The decrease over the comparable period in 2011 was due primarily to lower personnel-related costs including performance-based incentive compensation.

Interest and financing expenses were $8.5 million for the second quarter of 2012 compared to $9.3 million for the second quarter of 2011, with this decrease due primarily to increases in interest capitalized on higher average construction project balances outstanding year over year.

Our second quarter 2012 effective income tax rate was 34.1 percent versus 21.7 percent in the second quarter of 2011. Excluding special items, our second quarter 2012 effective income tax rate was 26.0 percent. Our effective tax rate continues to be influenced by the level and geographic mix of income, and benefits from a favorable mix of income in lower tax jurisdictions.

 

2


Cash Flow

Our cash flow from operations was approximately $185 million for the six months ended June 30, 2012, and we had $461.8 million in cash and cash equivalents at June 30, 2012. In the first half of 2012, cash on hand and cash provided by operations funded capital expenditures for plant, machinery and equipment of approximately $126.6 million (which includes approximately $44.0 million in capital expenditures associated with our Jordanian joint venture), long-term debt repayments of $9.4 million, dividends to shareholders of $33.4 million and repurchases of $13.7 million of our common stock.

Outlook

Uncertainty persists regarding the condition of the global economy. During the second quarter, we saw a steady deterioration of certain of the indicators that we use to gauge the health of and demand in the markets that our businesses serve, particularly within electronics. In addition, Catalysts will face challenging year-over-year comparisons.

Earnings Call

The Company’s performance for the second quarter ended June 30, 2012 will be discussed on a conference call at 9:00 AM Eastern Daylight time on July 18, 2012. The call can be accessed by dialing 800-638-5439 (International Dial In # 617-614-3945), and entering conference ID 95471699. The Company’s earnings presentation and supporting material can be accessed through Albemarle’s website under Investors at www.albemarle.com.

About Albemarle

Albemarle Corporation, headquartered in Baton Rouge, Louisiana, is a leading global developer, manufacturer and marketer of highly-engineered specialty chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, automotive/transportation, pharmaceuticals, crop protection, food-safety and custom chemistry services. Albemarle is committed to global sustainability and is advancing its eco-practices and solutions in its three business segments, Polymer Solutions, Catalysts and Fine Chemistry, with Corporate Responsibility Magazine naming Albemarle among its prestigious “100 Best Corporate Citizens” list for 2011. Albemarle employs more than 4,000 people worldwide and serves customers in approximately 100 countries. Albemarle regularly posts information to www.albemarle.com, including notification of events, news, financial performance, investor presentations and webcasts, Regulation G reconciliations, SEC filings and other information regarding the Company, its businesses and markets served.

Forward-Looking Statements

Some of the information presented in this press release, including, without limitation, statements with respect to product development, improvements in productivity, market trends, price and mix changes, expected growth, outlook and all other information relating to matters that are not historical facts may constitute forward-looking

 

3


statements within the meaning of the Private Securities Litigation Reform Act of 1995. There can be no assurance that actual results will not differ materially. Factors that could cause actual results to differ from expectations include, without limitation: changes in economic and business conditions; changes in financial and operating performance of our major customers and industries and markets served by us; the timing of orders received from customers; the gain or loss of significant customers; competition from other manufacturers; changes in the demand for our products; limitations or prohibitions on the manufacture and sale of our products; availability of raw materials; changes in the cost of raw materials and energy and in our inability to pass through increases; acquisitions and divestitures, and changes in performance of acquired companies; fluctuations in foreign currencies; changes in laws and government regulation impacting our operations or our products; the occurrence of claims or litigation; the occurrence of natural disasters; the inability to maintain current levels of product or premises liability insurance or the denial of such coverage; political unrest, including terrorism or hostilities; political instability affecting our manufacturing operations or joint ventures; changes in accounting standards; the inability to achieve results from our global manufacturing cost reduction initiatives as well as our ongoing continuous improvement and rationalization programs; changes in the jurisdictional mix of our earnings; changes in monetary policies or inflation or interest rates, which may impact our ability to raise capital or increase our cost of funds, the performance of our pension fund investments and our pension expense and funding obligations; volatility and substantial uncertainties in the debt and equity markets; technology or intellectual property infringement and other risks; decisions we may make in the future; and the other factors detailed from time to time in the reports we file with the SEC, including those described under “Risk Factors” in our Annual Report on Form 10-K and our 2012 Quarterly Reports on Form 10-Q.

 

4


Albemarle Corporation and Subsidiaries

Consolidated Statements of Income

(In Thousands Except Per Share Amounts) (Unaudited)

 

     Three Months Ended
June 30,
    Six Months Ended
June 30,
 
     2012     2011     2012     2011  

Net sales

   $ 684,894      $ 742,108      $ 1,396,598      $ 1,438,638   

Cost of goods sold

     442,209        490,159        906,026        953,673   
  

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

     242,685        251,949        490,572        484,965   

Selling, general and administrative expenses (a)

     74,624        82,907        155,316        155,946   

Research and development expenses

     20,911        19,947        39,960        37,562   

Restructuring and other charges (b)

     94,703        —          94,703        —     
  

 

 

   

 

 

   

 

 

   

 

 

 

Operating profit

     52,447        149,095        200,593        291,457   

Interest and financing expenses

     (8,486     (9,274     (17,220     (18,866

Other expenses, net

     (688     (760     (806     (422
  

 

 

   

 

 

   

 

 

   

 

 

 

Income before income taxes and equity in net income of unconsolidated investments

     43,273        139,061        182,567        272,169   

Income tax expense

     14,747        30,154        50,213        62,326   
  

 

 

   

 

 

   

 

 

   

 

 

 

Income before equity in net income of unconsolidated investments

     28,526        108,907        132,354        209,843   

Equity in net income of unconsolidated investments (net of tax)

     12,712        14,787        21,298        27,618   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income

     41,238        123,694        153,652        237,461   

Net income attributable to noncontrolling interests

     (3,506     (9,535     (7,877     (16,722
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributable to Albemarle Corporation

   $ 37,732      $ 114,159      $ 145,775      $ 220,739   
  

 

 

   

 

 

   

 

 

   

 

 

 

Basic earnings per share

   $ 0.42      $ 1.24      $ 1.63      $ 2.41   

Diluted earnings per share

   $ 0.42      $ 1.23      $ 1.62      $ 2.38   

Weighted-average common shares outstanding – basic

     89,414        91,713        89,206        91,673   

Weighted-average common shares outstanding – diluted

     90,051        92,795        89,999        92,656   

See accompanying notes to the condensed consolidated financial information.

 

5


Albemarle Corporation and Subsidiaries

Condensed Consolidated Balance Sheets

(In Thousands) (Unaudited)

 

     June 30,
2012
     December 31,
2011
 

ASSETS

     

Cash and cash equivalents

   $ 461,751       $ 469,416   

Other current assets

     989,924         886,204   
  

 

 

    

 

 

 

Total current assets

     1,451,675         1,355,620   
  

 

 

    

 

 

 

Property, plant and equipment

     2,725,084         2,619,428   

Less accumulated depreciation and amortization

     1,548,114         1,489,948   
  

 

 

    

 

 

 

Net property, plant and equipment

     1,176,970         1,129,480   

Other assets and intangibles

     674,062         718,724   
  

 

 

    

 

 

 

Total assets

   $ 3,302,707       $ 3,203,824   
  

 

 

    

 

 

 

LIABILITIES AND EQUITY

     

Current portion of long-term debt

   $ 12,572       $ 14,416   

Other current liabilities

     400,731         386,762   
  

 

 

    

 

 

 

Total current liabilities

     413,303         401,178   
  

 

 

    

 

 

 

Long-term debt

     742,252         749,257   

Other noncurrent liabilities

     283,007         296,659   

Deferred income taxes

     70,501         77,903   

Albemarle Corporation shareholders’ equity

     1,705,690         1,591,277   

Noncontrolling interests

     87,954         87,550   
  

 

 

    

 

 

 

Total liabilities & equity

   $ 3,302,707       $ 3,203,824   
  

 

 

    

 

 

 

See accompanying notes to the condensed consolidated financial information.

 

6


Albemarle Corporation and Subsidiaries

Selected Consolidated Cash Flow Data

(In Thousands) (Unaudited)

 

     Six Months Ended
June 30,
 
     2012     2011  

Cash and cash equivalents at beginning of year

   $ 469,416      $ 529,650   

Cash and cash equivalents at end of period

   $ 461,751      $ 490,715   

Sources of cash and cash equivalents:

    

Net income

     153,652        237,461   

Proceeds from borrowings

     614        14,558   

Proceeds from exercise of stock options

     13,430        1,082   

Uses of cash and cash equivalents:

    

Capital expenditures

     (126,623     (67,627

Repurchases of common stock

     (13,695     —     

Repayments of long-term debt

     (9,383     (105,206

Dividends paid to shareholders

     (33,399     (27,960

Pension and postretirement contributions

     (4,612     (55,751

Investments in equity and other corporate investments

     —          (10,868

Long-term advances to joint venture

     (10,000     —     

Non-cash items:

    

Depreciation and amortization

     49,449        47,310   

Restructuring and other charges (b)

     94,703        —     

Equity in net income of unconsolidated investments

     (21,298     (27,618

See accompanying notes to the condensed consolidated financial information.

 

7


Albemarle Corporation and Subsidiaries

Consolidated Summary of Segment Results

(In Thousands) (Unaudited)

 

     Three Months Ended
June 30,
    Six Months Ended
June 30,
 
     2012     2011     2012     2011  

Net sales:

        

Polymer Solutions

   $ 247,016      $ 290,450      $ 475,147      $ 548,673   

Catalysts

     229,144        266,851        522,666        527,808   

Fine Chemistry

     208,734        184,807        398,785        362,157   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total net sales

   $ 684,894      $ 742,108      $ 1,396,598      $ 1,438,638   
  

 

 

   

 

 

   

 

 

   

 

 

 

Segment operating profit:

        

Polymer Solutions

   $ 61,811      $ 78,850      $ 114,523      $ 148,681   

Catalysts

     56,304        53,438        131,719        115,569   

Fine Chemistry

     47,583        42,635        89,507        76,594   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total segment operating profit

     165,698        174,923        335,749        340,844   
  

 

 

   

 

 

   

 

 

   

 

 

 

Equity in net income of unconsolidated investments:

        

Polymer Solutions

     1,913        2,650        3,758        5,139   

Catalysts

     10,799        12,165        17,540        22,626   

Fine Chemistry

     —          —          —          —     

Corporate & other

     —          (28     —          (147
  

 

 

   

 

 

   

 

 

   

 

 

 

Total equity in net income of unconsolidated investments

     12,712        14,787        21,298        27,618   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net (income) loss attributable to noncontrolling interests:

        

Polymer Solutions

     349        (4,333     (653     (7,179

Catalysts

     —          —          —          —     

Fine Chemistry

     (3,832     (5,225     (7,204     (9,650

Corporate & other

     (23     23        (20     107   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total net income attributable to noncontrolling interests

     (3,506     (9,535     (7,877     (16,722
  

 

 

   

 

 

   

 

 

   

 

 

 

Segment income:

        

Polymer Solutions

     64,073        77,167        117,628        146,641   

Catalysts

     67,103        65,603        149,259        138,195   

Fine Chemistry

     43,751        37,410        82,303        66,944   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total segment income

     174,927        180,180        349,190        351,780   

Corporate & other

     (18,571     (25,833     (40,473     (49,427

Restructuring and other charges (b)

     (94,703     —          (94,703     —     

Interest and financing expenses

     (8,486     (9,274     (17,220     (18,866

Other expenses, net

     (688     (760     (806     (422

Income tax expense

     (14,747     (30,154     (50,213     (62,326
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributable to Albemarle Corporation

   $ 37,732      $ 114,159      $ 145,775      $ 220,739   
  

 

 

   

 

 

   

 

 

   

 

 

 

See accompanying notes to the condensed consolidated financial information.

 

8


Notes to the Condensed Consolidated Financial Information

 

(a) The six month period ended June 30, 2012 includes a gain of $8.1 million ($5.1 million after tax, or 6 cents per share) resulting from proceeds received in connection with the settlement of litigation (net of related legal fees). The six month period ended June 30, 2012 also includes an $8 million charitable contribution ($5.1 million after tax, or 6 cents per share) to the Albemarle Foundation.
(b) The three and six month periods ended June 30, 2012 include charges amounting to $94.7 million ($73.6 million after income taxes, or $0.82 per share) in connection with our previously announced plan to exit the phosphorous flame retardants business

Additional Information

It should be noted that earnings, earnings per share and effective income tax rates which exclude special items, as well as presentations of segment operating profit, segment income, EBITDA, EBITDA excluding special items, EBITDA margin and EBITDA margin excluding special items are financial measures that are not required by, or presented in accordance with, accounting principles generally accepted in the United States, or GAAP. These measures are presented here to provide additional useful measurements to review our operations, provide transparency to investors and enable period-to-period comparability of financial performance.

A description of other non-GAAP financial measures that we use to evaluate our operations and financial performance, and reconciliation of these non-GAAP financial measures to the most directly comparable financial measures calculated and reported in accordance with GAAP, can be found in the Investors section of our website at www.albemarle.com, under “Non-GAAP Reconciliations” under “Financials.” Also, see attached for a supplemental reconciliation of our segment operating profit and segment income amounts to GAAP Operating profit and GAAP Net income attributable to Albemarle Corporation, respectively, as well as for a supplemental reconciliation of our GAAP Net income attributable to Albemarle Corporation to EBITDA and EBITDA excluding special items.

 

9


ALBEMARLE CORPORATION AND SUBSIDIARIES

Non-GAAP Reconciliation

(In Thousands)

(Unaudited)

Our segment information includes measures we refer to as “segment operating profit,” “segment income,” “EBITDA” and “EBITDA excluding special items,” which are financial measures that are not required by, or presented in accordance with, GAAP. The Company has reported segment operating profit, segment income, EBITDA and EBITDA excluding special items because management believes that these financial measures provide transparency to investors and enable period-to-period comparability of financial performance. Segment operating profit, segment income, EBITDA and EBITDA excluding special items should not be considered as alternatives to operating profit or net income attributable to Albemarle Corporation, as determined in accordance with GAAP.

See below for a reconciliation of segment operating profit and segment income, the non-GAAP financial measures, to Operating profit and Net income attributable to Albemarle Corporation, respectively, the most directly comparable financial measures calculated and reported in accordance with GAAP.

 

     Three Months Ended
June 30,
    Six Months Ended
June 30,
 
     2012     2011     2012     2011  

Total segment operating profit

   $ 165,698      $ 174,923      $ 335,749      $ 340,844   

Corporate & other *

     (18,548     (25,828     (40,453     (49,387

Restructuring and other charges

     (94,703     —          (94,703     —     
  

 

 

   

 

 

   

 

 

   

 

 

 

GAAP Operating profit

   $ 52,447      $ 149,095      $ 200,593      $ 291,457   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total segment income

   $ 174,927      $ 180,180      $ 349,190      $ 351,780   

Corporate & other

     (18,571     (25,833     (40,473     (49,427

Restructuring and other charges

     (94,703     —          (94,703     —     

Interest and financing expenses

     (8,486     (9,274     (17,220     (18,866

Other expenses, net

     (688     (760     (806     (422

Income tax expense

     (14,747     (30,154     (50,213     (62,326
  

 

 

   

 

 

   

 

 

   

 

 

 

GAAP Net income attributable to Albemarle Corporation

   $ 37,732      $ 114,159      $ 145,775      $ 220,739   
  

 

 

   

 

 

   

 

 

   

 

 

 

 

* Excludes corporate equity income and noncontrolling interest adjustments of $(23) and $(5) for the three-month periods ended June 30, 2012 and 2011, respectively, and $(20) and $(40) for the six-month periods ended June 30, 2012 and 2011, respectively.

 

10


See below for a reconciliation of EBITDA and EBITDA excluding special items, the non-GAAP financial measures, from net income attributable to Albemarle Corporation, the most directly comparable financial measure calculated and reported in accordance with GAAP. EBITDA is defined as Net income attributable to Albemarle Corporation before interest and financing expenses, income taxes, depreciation and amortization. EBITDA excluding special items is defined as EBITDA before the special items as listed below.

 

     Three Months Ended
June 30,
    Six Months Ended
June 30,
 
     2012     2011     2012     2011  

Net income attributable to Albemarle Corporation

   $ 37,732      $ 114,159      $ 145,775      $ 220,739   
  

 

 

   

 

 

   

 

 

   

 

 

 

Add:

        

Interest and financing expenses

     8,486        9,274        17,220        18,866   

Income tax expense

     14,747        30,154        50,213        62,326   

Depreciation and amortization

     25,214        24,306        49,449        47,310   
  

 

 

   

 

 

   

 

 

   

 

 

 

EBITDA

     86,179        177,893        262,657        349,241   

Restructuring and other charges

     94,703        —          94,703        —     
  

 

 

   

 

 

   

 

 

   

 

 

 

EBITDA excluding special items

   $ 180,882      $ 177,893      $ 357,360      $ 349,241   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net sales

   $ 684,894      $ 742,108      $ 1,396,598      $ 1,438,638   
  

 

 

   

 

 

   

 

 

   

 

 

 

EBITDA Margin

     12.6     24.0     18.8     24.3
  

 

 

   

 

 

   

 

 

   

 

 

 

EBITDA Margin excluding special items

     26.4     24.0     25.6     24.3
  

 

 

   

 

 

   

 

 

   

 

 

 

 

11